Combined R-α-lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinson's disease

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 1-2, 2010, Pages 215-225

  Zhang, Hongyu ^a,f   Jia, Haiqun ^a,b   Liu, Jianghai ^a   Ao, Ni ^a   Yan, Bing ^a,b   Shen, Weili ^a   Wang, Xuemin ^c   Li, Xin ^a   Luo, Cheng ^a   Liu, Jiankang ^d,e  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e XI'AN JIAOTONG UNIVERSITY   (China)

^f LUND UNIVERSITY   (Sweden)

Author keywords

Acetyl L carnitine; Lipoic acid; Mitochondrial dysfunction; Oxidative damage; Parkinson's disease

Indexed keywords

ACETYLCARNITINE; ALPHA SYNUCLEIN; ANTIOXIDANT; ROTENONE; THIOCTIC ACID; UBIQUITIN; UNCOUPLING PROTEIN;

ARTICLE; DRUG EFFECT; DRUG POTENTIATION; HUMAN; METABOLISM; MITOCHONDRION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARKINSON DISEASE;

ACETYLCARNITINE; ALPHA-SYNUCLEIN; ANTIOXIDANTS; DRUG SYNERGISM; HUMANS; MITOCHONDRIA; OXIDATION-REDUCTION; OXIDATIVE STRESS; PARKINSON DISEASE; ROTENONE; THIOCTIC ACID; UBIQUITIN; UNCOUPLING AGENTS;

EID: 77951950272     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00390.x     Document Type: Article

References (35)

1. Moore DJ, West AB, Dawson VL. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci. 2005, 28:57-87.
2. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol. 2003, 53:S26-36. discussion S-8
3. Liu J, Ames BN. Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer's disease, and Parkinson's disease. Nutr Neurosci. 2005, 8:67-89.
4. Liu J. The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview. Neurochem Res. 2008, 33:194-203.
5. Beal MF. Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann Neurol. 2003, 53:S39-47. discussion S-8
6. Beal MF, Matthews RT, Tieleman A. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. 1998, 783:109-14.
7. Shults CW, Oakes D, Kieburtz K. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002, 59:1541-50.
8. St-Pierre J, Drori S, Uldry M. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell. 2006, 127:397-408.
9. Cui L, Jeong H, Borovecki F. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell. 2006, 127:59-69.
10. Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med. 1995, 19:227-50.
11. Suh JH, Shenvi SV, Dixon BM. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc Natl Acad Sci USA. 2004, 101:3381-6.
12. Liu J, Atamna H, Kuratsune H. Delaying brain mitochondrial decay and aging with mitochondrial antioxidants and metabolites. Ann New York Acad Sci. 2002, 959:133-66.
13. Mazzio E, Yoon KJ, Soliman KF. Acetyl-L-carnitine cytoprotection against 1-methyl-4-phenylpyridinium toxicity in neuroblastoma cells. Biochem Pharmaco. 2003, 66:297-306.
14. Bodis-Wollner I, Chung E, Ghilardi MF. Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates. J Neural Transm Park Dis Dement Sect. 1991, 3:63-72.
15. Bharat S, Cochran BC, Hsu M. Pre-treatment with R-lipoic acid alleviates the effects of GSH depletion in PC12 cells: implications for Parkinson's disease therapy. Neurotoxicology. 2002, 23:479-86.
16. Karunakaran S, Diwakar L, Saeed U. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid. FASEB J. 2007, 21:2226-36.
17. Sherer TB, Betarbet R, Stout AK. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci. 2002, 22:7006-15.
18. Janssen AJ, Trijbels FJ, Sengers RC. Spectrophotometric assay for complex I of the respiratory chain in tissue samples and cultured fibroblasts. Clin Chem. 2007, 53:729-34.
19. Smiley ST, Reers M, Mottola-Hartshorn C. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci USA. 1991, 88:3671-5.
20. Fukuyama R, Nakayama A, Nakase T. A newly established neuronal rho-0 cell line highly susceptible to oxidative stress accumulates iron and other metals. Relevance to the origin of metal ion deposits in brains with neurodegenerative disorders. J Biol Chem. 2002, 277:41455-62.
21. Royall JA, Ischiropoulos H. Evaluation of 2′,7′-dichlorofluorescin and dihydrorhodamine 123 as fluorescent probes for intracellular H2O2 in cultured endothelial cells. Arch Biochem Biophys. 1993, 302:348-55.
22. Olive PL, Durand RE. Heterogeneity in DNA damage using the comet assay. Cytometry A. 2005, 66:1-8.
23. Kuroda Y, Mitsui T, Kunishige M. Parkin enhances mitochondrial biogenesis in proliferating cells. Hum Mol Genet. 2006, 15:883-95.
24. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet. 2005, 39:359-407.
25. Dawson TM, Dawson VL. Neuroprotective and neurorestorative strategies for Parkinson's disease. Nat Neurosci. 2002, 5:1058-61.
26. Olanow CW, Jankovic J. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord. 2005, 20:S3-10.
27. Kedar NP. Can we prevent Parkinson's and Alzheimer's disease. J Postgrad Med. 2003, 49:236-45.
28. Stadtman ER. Protein oxidation and aging. Free Radic Res. 2006, 40:1250-8.
29. Liu J, Killilea DW, Ames BN. Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L-carnitine and/or R-alpha -lipoic acid. Proc Natl Acad Sci USA. 2002, 99:1876-81.
30. Liu J, Head E, Gharib AM. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha-lipoic acid. Proc Natl Acad Sci USA. 2002, 99:2356-61.
31. Hagen TM, Liu J, Lykkesfeldt J. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc Natl Acad Sci USA. 2002, 99:1870-5.
32. Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med. 1998, 339:1044-53.
33. Lang AE, Lozano AM. Parkinson's disease. Second of two parts. N Engl J Med. 1998, 339:1130-43.
34. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998, 279:1200-5.
35. Betarbet R, Sherer TB, Greenamyre JT. Animal models of Parkinson's disease. Bioessays. 2002, 24:308-18.